Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Crizotinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 6,826Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ideaya Biosciences to Unveil Phase 2 Darovasertib/Crizotinib
    Ideaya Biosciences to Unveil Phase 2 Darovasertib/Crizotinib

    30 Aug 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-to-present-first-median-overall-survival-data-from-phase-2-trial-of-the-darovasertib--crizotinib-combination-in-metastatic-uveal-melanoma-at-the-2025-society-for-melanoma-research-congress-302542236.html

    PR NEWSWIRE
    30 Aug 2025
    Share Share
    IDEAYA Bio gets FDA Breakthrough for Darovasertib in Uvea Melanoma
    IDEAYA Bio gets FDA Breakthrough for Darovasertib in Uvea Melanoma

    31 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-receives-us-fda-breakthrough-therapy-designation-for-darovasertib-monotherapy-in-neoadjuvant-uveal-melanoma-302415020.html

    PR NEWSWIRE
    31 Mar 2025
    Share Share
    Nuvation To Present Taletrectinib Vs. Crizotinib Data At Lung Congress
    Nuvation To Present Taletrectinib Vs. Crizotinib Data At Lung Congress

    25 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250325247942/en/Nuvation-Bio-to-Present-Matching-adjusted-Indirect-Comparison-Data-for-Taletrectinib-vs.-Crizotinib-During-Mini-Oral-Presentation-at-the-European-Lung-Cancer-Congress-2025

    BUSINESSWIRE
    25 Mar 2025
    Share Share
    Pfizer's LORBRENA Showed 5+ Year PFS In ALK+ Lung Cancer CROWN Study
    Pfizer's LORBRENA Showed 5+ Year PFS In ALK+ Lung Cancer CROWN Study

    01 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240530259641/en

    BUSINESSWIRE
    01 Jun 2024
    Share Share
    IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023
    IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023

    17 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-proffered-paper-oral-presentation-at-esmo-2023-for-phase-2-clinical-data-update-for-darovasertib-and-crizotinib-combination-in-metastatic-uveal-melanoma-301958315.html

    PR NEWSWIRE
    17 Oct 2023
    Share Share
    IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib
    IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib

    16 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-phase-2-expansion-of-darovasertib-and-crizotinib-combination-in-gnaq11-metastatic-cutaneous-melanoma-301956860.html

    PR NEWSWIRE
    16 Oct 2023
    Share Share